Description

2-[4-(Difluoromethyl)-6-(3-Methoxyphenyl)-3-Methyl-Pyrazolo[3,4-B]Pyridin-1-Yl]Acetic Acid is a high-purity, advanced pharmaceutical intermediate with a complex heterocyclic structure. This compound is valued for its role as a critical building block in the synthesis of novel active pharmaceutical ingredients (APIs), particularly in therapeutic areas requiring targeted molecular design. It is primarily utilized by research institutions and pharmaceutical manufacturers engaged in the development of new chemical entities and specialty fine chemicals.

Application

• Pharmaceutical Intermediate: A key precursor in the research and synthesis of novel drug candidates, especially in oncology and central nervous system (CNS) therapeutic areas.
• Chemical Research & Development: Serves as a sophisticated scaffold for medicinal chemists exploring structure-activity relationships (SAR) and developing new heterocyclic compounds.
• Active Pharmaceutical Ingredient (API) Synthesis: Used in the multi-step synthesis of complex target molecules for preclinical and clinical studies.
• Contract Manufacturing (CMO): Supplied to contract manufacturing organizations for the production of specialized, high-value compounds under cGMP conditions.
• Academic Research: Employed in university and institutional labs for advanced organic synthesis projects and the study of pyrazolopyridine chemistry.

Basic Information

Product Name	2-[4-(Difluoromethyl)-6-(3-Methoxyphenyl)-3-Methyl-Pyrazolo[3,4-B]Pyridin-1-Yl]Acetic Acid
CAS No.	937607-17-5
Molecular Formula	C19H17F2N3O3
Molecular Weight	373.36 g/mol
Synonyms	2-[4-(Difluoromethyl)-6-(3-methoxyphenyl)-3-methylpyrazolo[3,4-b]pyridin-1-yl]acetic acid; 1-(Carboxymethyl)-4-(difluoromethyl)-6-(3-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine; 937607-17-5; (4-(Difluoromethyl)-6-(3-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-1-yl)acetic acid; DFMPMPA (abbreviation); Pyrazolopyridine acetic acid derivative
EINECS	Contact for details

Quality Control

Our production of 2-[4-(Difluoromethyl)-6-(3-Methoxyphenyl)-3-Methyl-Pyrazolo[3,4-B]Pyridin-1-Yl]Acetic Acid adheres to stringent quality protocols suitable for pharmaceutical R&D and manufacturing. Each batch undergoes comprehensive analytical testing, including HPLC for purity, NMR and IR for structural confirmation, and residual solvent analysis. Certificates of Analysis (COA) detailing all specifications are provided with every shipment to ensure full traceability and compliance with your internal quality standards.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (15-25°C). The product is light-sensitive and should be handled under appropriate conditions to maintain stability. Keep the container tightly sealed when not in use to protect from moisture.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Conforms to reference
Purity (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.